Palliative chemotherapy in patients with salivary gland neoplasms and preliminary reports of 2 recent phase II studies with trastuzumab and gemcitabine.

Abstract	Salivary gland malignancies are a diverse group of neoplasms. Patients are usually treated with surgery followed by adjuvant radiation therapy. Those presenting with recurrent or metastatic disease have limited treatment options for these patients and discuss the results of 2 recent studies that used trastuzumab and gemcitabine as single agents in patients with incurable disease.
Authors	Robert Haddad, Marshall R Posner
Journal	Clinical advances in hematology & oncology : H&O (Clin Adv Hematol Oncol) Vol. 1 Issue 4 Pg. 226-8 (Apr 2003) ISSN: 1543-0790 [Print] United States
PMID	16224411 (Publication Type: Journal Article, Review)
Chemical References	Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Deoxycytidine Trastuzumab Gemcitabine
Topics	Antibodies, Monoclonal (therapeutic use) Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols (therapeutic use) Clinical Trials, Phase II as Topic Deoxycytidine (analogs & derivatives, therapeutic use) Humans Palliative Care Salivary Gland Neoplasms (drug therapy) Trastuzumab Gemcitabine

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!